Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Bovine Heparin Demonstrates the Same Interaction with HIT Antibodies As Porcine Heparin

Jeanine Walenga, PhD, Walter Jeske, PhD, Sabrina Bertini, Giulia Risi, Michelle Sung, BS, Ambar Farooqui, Cassie Bacher, Debra Hoppensteadt, PhD, Omer Iqbal, MD, Bruce Lewis, Mamdouh Bakhos, MD

Blood (2019) 134 (Supplement_1): 2351.

https://doi.org/10.1182/blood-2019-127304

Published: 2019

Journal Articles

Defining Primary Marrow Microenvironment-Induced Synthetic Lethality and Resistance for 2,684 Approved Drugs Across Molecularly Distinct Forms of Multiple Myeloma

Megan Murnane, M.Sc., Eugen Dhimolea, PhD, Ruojing Li, BS, Megan A. Bariteau, BSc, Diamond D. Wheeler, BS, Rosemary J. Akhurst, PhD, Aaron C. Logan, MD PhD, Pamela Munster, MD, Arun Wiita, MD PhD, Thomas G. Martin, III, MD, Jeffrey L. Wolf, MD PhD, Jun O. Liu, PhD, Constantine S. Mitsiades, MD PhD, Blake T. Aftab, PhD

Blood (2015) 126 (23): 503.

https://doi.org/10.1182/blood.V126.23.503.503

Published: 2015

Journal Articles

The Rheumatoid Arthritis Drug Auranofin Has Significant in Vitro Activity in MCL and DLCL and Is Synergistic with a Glutathione Depleting Agent

Jolanta Skalska, PhD, Michelle M. Kiebala, PhD, Shannon P. Hilchey, PhD, Yun Dai, MD, PhD, Steven Grant, MD, Paul S. Brookes, PhD, Derick R. Peterson, PhD, Sanjay B. Maggirwar, PhD, Steven H. Bernstein, MD

Blood (2012) 120 (21): 1658.

https://doi.org/10.1182/blood.V120.21.1658.1658

Published: 2012

Journal Articles

Comparative Antithrombotic and Bleeding Effects of Two U.S. Generic Enoxaparins

Walter Jeske, PhD, Jeanine M. Walenga, PhD, Vicki Escalante, BS, Debra Hoppensteadt, Josephine Cunanan, MD, Daniel Kahn, Anwar Akhras, Michelle Paulus, Jawed Fareed, PhD, Mamdouh Bakhos, MD

Blood (2012) 120 (21): 1172.

https://doi.org/10.1182/blood.V120.21.1172.1172

Published: 2012

Journal Articles

Development of a Cancer Pharmacopeia-Wide Ex-Vivo Drug Sensitivity and Resistance Testing (DSRT) Platform: Identification of MEK and mTOR As Patient-Specific Molecular Drivers of Adult AML and Potent Therapeutic Combinations with Dasatinib

Mika Kontro, MD, Caroline Heckman, PhD, Evgeny Kulesskiy, MSc, Tea Pemovska, MSc, Maxim Bespalov, PhD, Samuli Eldfors, MSc, Elonen Erkki, MD, PhD, Riikka Karjalainen, MSc, Jonathan Knowles, PhD, Disha Malani, MSc, Muntasir Mamun Majumder, MSc, John Patrick Mpindi, MSc, PhD, Astrid Murumägi, PhD, Satu Mustjoki, MD, PhD, Laura Turunen, MSc, Maija Wolf, PhD, Kimmo Porkka, MD, PhD, Krister Wennerberg, PhD, Olli Kallioniemi, MD, PhD

Blood (2011) 118 (21): 2487.

https://doi.org/10.1182/blood.V118.21.2487.2487

Published: 2011

NARROW

Bovine Heparin Demonstrates the Same Interaction with HIT Antibodies As Porcine Heparin

Defining Primary Marrow Microenvironment-Induced Synthetic Lethality and Resistance for 2,684 Approved Drugs Across Molecularly Distinct Forms of Multiple Myeloma

The Rheumatoid Arthritis Drug Auranofin Has Significant in Vitro Activity in MCL and DLCL and Is Synergistic with a Glutathione Depleting Agent

Comparative Antithrombotic and Bleeding Effects of Two U.S. Generic Enoxaparins

Development of a Cancer Pharmacopeia-Wide Ex-Vivo Drug Sensitivity and Resistance Testing (DSRT) Platform: Identification of MEK and mTOR As Patient-Specific Molecular Drivers of Adult AML and Potent Therapeutic Combinations with Dasatinib

Email alerts

ASH Publications

American Society of Hematology

Bovine Heparin Demonstrates the Same Interaction with HIT Antibodies As Porcine Heparin

Defining Primary Marrow Microenvironment-Induced Synthetic Lethality and Resistance for 2,684 Approved Drugs Across Molecularly Distinct Forms of Multiple Myeloma

The Rheumatoid Arthritis Drug Auranofin Has Significant in Vitro Activity in MCL and DLCL and Is Synergistic with a Glutathione Depleting Agent

Comparative Antithrombotic and Bleeding Effects of Two U.S. Generic Enoxaparins

Development of a Cancer Pharmacopeia-Wide Ex-Vivo Drug Sensitivity and Resistance Testing (DSRT) Platform: Identification of MEK and mTOR As Patient-Specific Molecular Drivers of Adult AML and Potent Therapeutic Combinations with Dasatinib

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only